Gwendolyn Wu - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Gwendolyn Wu's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Gwendolyn Wu

Gwendolyn Wu

Verified

Reporter, BioPharma Dive

San Francisco

Final Covers

travel, entrepreneurshipFreelancing, small business AI, creativity parenting, content marketing cruising

Doesn’t Cover

I do not cover sports or entertainment news.

Journalist Type

-

Seniority Positions

-

Industries

Medium Formats

-

Content

Total articles 2747

  • An investment fund sets out to free biotech’s ‘trapped capital’

    By Gwendolyn Wu Verified| BioPharma Dive Verified A British investment fund has launched with plans to extract tens of billions of dollars it believes to be “trapped” on the balance sheets of struggling, publicly traded biotechnology companies.  Called Alis Biosciences, the fund aims to return to shareholders the cash invested in these biotechs, while still supporting the companies’ management and boards, according to a Friday statement announcing its debut.

    By Gwendolyn Wu Verified · BioPharma Dive

    Apr. 18, 2025

  • Bluebird says Ayrmid missed deadline for rival takeover bid

    By Gwendolyn Wu Verified| BioPharma Dive Verified Bluebird bio is still waiting on a binding takeover bid from Ayrmid Ltd., three weeks after the company said it would pay $15 million more than SK Capital and Carlyle Group offered for the gene therapy maker. In a Wednesday statement, Bluebird board chair Mark Vachon said Ayrmid has yet to present a binding offer or acquire the financing necessary to complete its $45 million proposal.

    By Gwendolyn Wu Verified · BioPharma Dive

    Apr. 16, 2025

  • An investment fund sets out to free biotech’s ‘trapped capital’

    By Gwendolyn Wu Verified| BioPharma Dive Verified A British investment fund has launched with plans to extract tens of billions of dollars it believes to be “trapped” on the balance sheets of struggling, publicly traded biotechnology companies.  Called Alis Biosciences, the fund aims to return to shareholders the cash invested in these biotechs, while still supporting the companies’ management and boards, according to a Friday statement announcing its debut.

    By Gwendolyn Wu Verified · BioPharma Dive

    Apr. 18, 2025

As seen in

Company Info

BioPharma Dive

Banking Dive is a prominent online publication dedicated to the banking industry. It offers in-depth journalism and analysis, providing valuable insights into the latest news, trends, and regulatory changes affecting the sector. As part of Industry Dive, which has merged with TechTarget's technology websites and Informa Tech, Banking Dive has expanded its editorial reach significantly. The platform features a variety of services, including detailed news coverage, a newsletter for subscribers, and deep dive articles that explore specific topics such as regulations and technology's role in banking. Banking Dive caters to professionals in the banking sector, including executives, policymakers, and financial analysts, delivering reliable information to help them navigate the evolving landscape of the industry.

Washington, District of Columbia, United States

+1 202-331-2480